Fulyzaq approved for ART-related diarrhea in HIV/AIDS

January 3, 2013
Fulyzaq approved for ART-related diarrhea in HIV/AIDS
The first medication to treat diarrhea in people with HIV/AIDS who take antiretroviral drugs has been approved by the U.S. Food and Drug Administration.

(HealthDay)—The first medication to treat diarrhea in people with HIV/AIDS who take antiretroviral drugs has been approved by the U.S. Food and Drug Administration.

Fulyzaq (crofelemer) is sanctioned for people whose diarrhea is not caused by an infection or but by the antiretroviral drugs used to combat HIV/AIDS, the FDA said in a news release. The drug is derived from the red sap of the Croton lechleri plant.

Fulyzaq's safety and effectiveness were evaluated in a clinical study involving 374 people who were HIV-positive, on stable drug therapy, and who had had diarrhea for one month or longer. About 17.6 percent of people who took Fulyzaq had a positive "clinical response," compared with a positive response among 8 percent of people who took a placebo.

All participants in the study were tested to confirm that their symptoms were not caused by an infection or , the FDA said. Common side effects to Fulyzaq's use were upper , bronchitis, cough, flatulence, and an increase in the liver enzyme bilirubin.

The drug is distributed by Salix Pharmaceuticals, based in Raleigh, N.C.

Explore further: Stivarga approved for advanced colorectal cancer

More information: More Information

Related Stories

Stivarga approved for advanced colorectal cancer

September 27, 2012
(HealthDay)—Stivarga (regorafenib) has been approved by the U.S. Food and Drug Administration to treat colorectal cancer that has spread despite prior treatment.

Xeljanz approved for rheumatoid arthritis

November 7, 2012
(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.

Afinitor approved for advanced breast cancer

July 23, 2012
(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration ...

Gattex approved for short bowel syndrome

December 22, 2012
(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.